Safety of ustekinumab in adolescent patients with moderate-to-severe plaque psoriasis: real-world evidence from an ongoing European study (NCT03218488)

J Eur Acad Dermatol Venereol. 2022 Aug;36(8):e646-e648. doi: 10.1111/jdv.18110. Epub 2022 Apr 6.

Authors

E Mahé¹, A Geldhof², M Jazra³, P Bergmans⁴, A Azzabi⁵, M M B Seyger⁶

Affiliations

¹ Department of Dermatology, Centre Hospitalier Victor Dupouy, Argenteuil, France.
² Medical Affairs, Janssen Biologics BV, Leiden, Netherlands.
³ Medical Affairs, Janssen-Cilag, Paris, France.
⁴ Biostatistics, Janssen-Cilag BV, Breda, Netherlands.
⁵ Medical Affairs, Janssen Near East, Maghreb & Africa, Casablanca, Morocco.
⁶ Department of Dermatology, Radboud University Medical Center, Nijmegen, Netherlands.

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Adolescent
Dermatologic Agents* / adverse effects
Humans
Longitudinal Studies
Psoriasis* / drug therapy
Severity of Illness Index
Treatment Outcome
Ustekinumab / adverse effects

Substances

Dermatologic Agents
Ustekinumab

Grants and funding

Janssen